| Source: |
| Type: |
| Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body. |
| 2878- | HNK, | Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9 |
| - | in-vitro, | Lung, | H1299 |
| 2882- | HNK, | Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling |
| - | in-vitro, | PC, | PANC1 |
| 2884- | HNK, | Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 2868- | HNK, | Honokiol: A review of its pharmacological potential and therapeutic insights |
| - | Review, | Var, | NA | - | Review, | Sepsis, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2898- | HNK, | Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | NCI-N87 | - | in-vitro, | BC, | MGC803 | - | in-vitro, | GC, | SGC-7901 |
| 1087- | HNK, | Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of β-Catenin Signaling |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H226 |
| 1153- | HNK, | Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 7469- | Hops, | CHEMOPREVENTIVE PROPERTIES OF SPENT HOPS (HUMULUS LUPULUS L.) EXTRACT AGAINST ANGIOGENESIS, INVASION AND MIGRATION OF COLORECTAL CANCER CELLS |
| - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | HT29 |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | BT549 |
| 4637- | HT, | Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells |
| - | in-vitro, | Nor, | RWPE-1 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | SUM159 |
| 7569- | HYP, | Inhibitory effects of hyperoside on lung cancer by inducing apoptosis and suppressing inflammatory response via caspase-3 and NF-κB signaling pathway |
| - | vitro+vivo, | Lung, | A549 |
| 7567- | HYP, | Hyperoside: A review on its sources, biological activities, and molecular mechanisms |
| - | Review, | Var, | NA |
| 7547- | HYP, | Hyperoside suppresses NSCLC progression by inducing ATG13-mediated autophagy and apoptosis |
| - | vitro+vivo, | NSCLC, | NA |
| 7549- | HYP, | Rad, | Study on the mechanism of hyperoside in affecting the biological progression and radiosensitivity of esophageal carcinoma by modulating the STAT3/AKT/ERK pathway |
| - | vitro+vivo, | ESCC, | TE1 | - | vitro+vivo, | ESCC, | KYSE150 |
| 7550- | HYP, | Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | 4T1 |
| 7582- | I3C, | Indole-3-Carbinol Promotes Apoptosis and Inhibits the Metastasis of Esophageal Squamous Cell Carcinoma by Downregulating the Wnt/β-Catenin Signaling Pathway |
| - | vitro+vivo, | ESCC, | NA |
| 7583- | I3C, | Indole-3-carbinol prevented tumor progression and potentiated PD1ab therapy by upregulating PTEN in colorectal cancer |
| - | vitro+vivo, | CRC, | NA |
| 7592- | I3C, | Indole-3-carbinol as a chemopreventive and anti-cancer agent |
| - | Review, | Var, | NA |
| 1278- | I3C, | Indole-3-carbinol inhibits prostate cancer cell migration via degradation of beta-catenin |
| - | in-vivo, | Pca, | DU145 |
| 7809- | IBC, | Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways |
| - | in-vitro, | GC, | MGC803 |
| 7695- | IP6, | The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1β-stimulated colon cancer cells |
| - | in-vitro, | Colon, | Caco-2 |
| 7701- | IP6, | Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-β-catenin-ABCG1 signaling pathway |
| - | vitro+vivo, | HCC, | Hep3B | - | NA, | NA, | MHCC-97H |
| 7744- | ISL, | Isoliquiritigenin suppresses fatty acid synthesis and cancer cell migration in anaplastic thyroid carcinoma through AMPK/SREBF1 pathway |
| - | vitro+vivo, | Thyroid, | NA |
| 7745- | ISL, | Isoliquiritigenin inhibits colorectal cancer progression by targeting the FGFR4/FASN mediated lipid metabolism pathway |
| - | in-vitro, | CRC, | NA |
| 7756- | ISL, | Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway |
| - | vitro+vivo, | BC, | MCF7 | - | vitro+vivo, | BC, | MDA-MB-231 |
| 7783- | ISL, | Isoliquiritigenin Inhibits Ovarian Cancer Metastasis by Reversing Epithelial-to-Mesenchymal Transition |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
| 7730- | isoFl, | Anticancer Potential of Isoflavones: A Narrative Overview of Mechanistic Insights and Experimental Evidence from the Past Ten Years |
| - | Review, | Var, | NA |
| 7869- | isoO, | Apoptosis induction and inhibition of invasion and migration in gastric cancer cells by Isoorientin studied using network pharmacology |
| - | in-vitro, | GC, | HGC27 |
| 7859- | isoO, | Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 7792- | ISQ, | Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | IEC-18 |
| 7845- | ISQ, | Isoquercitrin, ingredients in Tetrastigma hemsleyanum Diels et Gilg, inhibits hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion |
| - | vitro+vivo, | Bladder, | NBT-II |
| 7997- | itraC, | Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway |
| - | vitro+vivo, | SCC, | NA |
| 8014- | itraC, | Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | NA |
| 8037- | IVM, | Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway |
| - | in-vitro, | Var, | NA |
| 8050- | IVM, | doxoR, | Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma |
| - | in-vitro, | OS, | NA |
| 8045- | IVM, | Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway |
| - | in-vitro, | Cerv, | HeLa |
| 8043- | IVM, | Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE70 | - | in-vitro, | ESCC, | KYSE150 |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 8007- | JG, | Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis |
| - | in-vitro, | GBM, | U251 |
| 7965- | JG, | Mechanistic investigation of Juglone (5-hydroxy-1,4-naphthoquinone) as an anti-cancer agent in human colorectal cancer HCT116 and HT-29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 1920- | JG, | TQ, | PLB, | Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line |
| - | in-vitro, | PC, | PANC1 |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 8089- | KAE, | Kaempferol impairs aerobic glycolysis against melanoma metastasis via inhibiting the mitochondrial binding of HK2 and VDAC1 |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | B16-F10 |
| - | in-vitro, | Melanoma, | A375 |
| 8071- | KAE, | Cellular reprogramming and signaling control by kaempferol in colorectal cancer |
| - | Review, | CRC, | NA |
| 8059- | KAE, | Kaempferol Inhibits Cervical Cancer Cells by Inducing Apoptosis and Autophagy via Inactivation of the PI3K/AKT/mTOR Signaling Pathway |
| - | in-vitro, | Cerv, | KB |
| 8064- | KAE, | Kaempferol Inhibits Pancreatic Cancer Cell Growth and Migration through the Blockade of EGFR-Related Pathway In Vitro |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | SNU-213 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:326 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid